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to countries with better provision of intensive care
units. However, for the United Kingdom, non-invasive
ventilation for patients with mild to moderate acidosis
due to decompensated chronic obstructive pulmonary
disease is a highly effective technique that improves
clinical outcomes, reduces demand for intensive care,
and, from the hospital’s perspective, reduces costs.
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Loss of tolerance and overdose mortality after inpatient
opiate detoxification: follow up study
John Strang, Jim McCambridge, David Best, Tracy Beswick, Jenny Bearn, Sian Rees, Michael Gossop
In many countries opiate overdose remains the main
source of the 10-fold excess mortality among opiate
addicts, notwithstanding the effects of HIV/AIDS.1
Treatment reduces mortality but can sometimes
increase mortality transiently—for example, during the
first few weeks of methadone maintenance treatment
and among former opiate addicts after their release
from prison.2 3 The increase in mortality among
released prisoners who were formerly opiate addicts
has been attributed to loss of tolerance and erroneous
judgment of dose when they returned to opiate use.1 3
We wished to investigate whether opiate addicts who
have undergone inpatient detoxification might have a
similarly increased mortality after treatment. We
followed up patients who received inpatient opiate
detoxification, looked for evidence of increased
mortality, and investigated the distinctive characteris-
tics of patients who died.
Participants, methods, and results
Over 20 months we recruited 137 consecutive opiate
addicts who were receiving opiate detoxification as
part of a 28 day inpatient treatment programme and
who consented to be followed up. Five patients died
within 12 months after their discharge from the
Predictors of mortality among patients who underwent inpatient opiate detoxification. Values are numbers (percentage) of patients
unless stated otherwise
Characteristic Patients who died (n=5) Other patients (n=132) Statistical test results
Mean age in years (SD) 31.4 (7.1) 32.6 (7.3) t=0.36, P=0.72
Male sex 5 (100) 99 (75) Fisher’s exact, P=0.34
Previous inpatient treatment 4 (80) 92 (70) Fisher’s exact, P=1.0
Ever overdosed 1 (20) 50† (39) Fisher’s exact, P=0.65
Was prescribed methadone* 5 (100) 92 (70) Fisher’s exact, P=0.32
Mean dose (mg) of prescribed methadone (SD) 51.0 (20.7) 29.2 (23.1) t=2.08, P=0.04
Mean number of days of heroin use* (SD) 14.4 (14.4) 24.5 (10.2) t=2.15, P=0.03
Living alone* 4 (80) 21† (16) Fisher’s exact, P=0.004
Physical health (MAP‡ score) (SD)* 38.6 (10.2) 29.9 (12.3) t=1.59, P=0.12
Mean length of stay (days) in unit (SD) 24.6 (7.6) 15.6 (8.1) t=2.44, P=0.02
Completed detoxification 5 (100) 89 (67) Fisher’s exact, P=0.33
Completed full treatment programme 4 (80) 33 (25) Fisher’s exact, P=0.02
*In the month before admission.
†Of 130 patients.
‡Maudsley Addiction Profile (see www.ntors.org.uk/map.pdf).
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inpatient unit, of whom three had died after a drug
overdose within the first four months after discharge.
We successfully interviewed 103 patients (at a mean
interval of 8.7 months after discharge). A search of
records indicated that the remaining 29 patients were
still alive one year after discharge.
To test whether loss of tolerance increased the risk
of overdose, we grouped the patients into three catego-
ries, according to their opiate tolerance at the point of
leaving treatment: 43 “still tolerant” (ST) patients who
failed to complete detoxification; 57 “reduced toler-
ance” (RT) patients who completed the prescribed
phase of detoxification but who prematurely left the
treatment programme; and 37 “lost tolerance” (LT)
patients who completed the detoxification and also
completed the inpatient treatment programme.
The three overdose deaths that occurred within
four months after treatment were all from the LT
group; the two deaths unrelated to overdose (although
both these patients had relapsed) were one LT patient
with end stage renal failure and one RT patient with
Clostridium welchii infection; no deaths occurred in the
ST group (Fisher’s exact test, df=2, P=0.02). This
clustering did not derive from differences in duration
to the follow up interview (mean durations were 9.5
months (ST), 8.7 months (RT), and 7.8 months (LT)).
We also considered length of time in treatment as a
continuous variable. The five patients who died had
stayed longer in the inpatient unit (mean 24.6 days (SD
7.6)) than the other 132 patients (15.6 days (8.1))
(t=2.44, P=0.02) (table). We looked for distinctive
premorbid characteristics among the patients, all men,
who died—possible clinical markers of risk of mortality
after detoxification. Before admission these patients
were more likely than the other patients to have been
living alone, to have been taking higher doses of
methadone, and to have been using heroin less often.
They stayed longer in the inpatient unit and were more
likely to have completed the treatment programme.
Comment
Patients who “successfully” completed inpatient
detoxification were more likely than other patients to
have died within a year. No patients who failed to
complete detoxification died. Heroin addicts are
known to have excess mortality.4 However, on the basis
of previously published data we would have expected
that in our group only one or two patients would have
died within a year and only one from overdose.5 The
clustering of the deaths from overdose in the group of
patients who had successfully completed treatment is
counterintuitive and illogical—unless it derives from
loss of tolerance and consequent unpredictability of
resumed heroin use. This study urgently requires rep-
lication, and if its results are confirmed these will need
to be addressed within existing inpatient, residential,
and custodial and associated aftercare programmes.
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Changing prescription patterns for lithium and valproic
acid in old age: shifting practice without evidence
Kenneth I Shulman, Paula Rochon, Kathy Sykora, Geoffrey Anderson, Muhammad Mamdani,
Susan Bronskill, Chau T T Tran
Over the past decade, valproic acid (prescribed as dival-
proex in North America) has been marketed as an alter-
native to lithium for treating bipolar disorders. For
elderly patients, however, there is no clear evidence that
valproic acid is more beneficial than lithium. Moreover,
the evidence for the superiority of valproic acid in treat-
ing bipolar disorders—mixed episodes and rapid
cycling—has been challenged in a recent Cochrane
review.1 Valproic acid has not benefited patients with
manic and psychiatric symptoms in dementia, despite
the growing use of the drug in the management of these
conditions.2 Recently, the relatively rapid shift in
prescription patterns has been questioned.3 We describe
trends in the use of lithium and valproic acid in a large
population of people over 65.
Methods and results
We obtained information on drug use from the
Ontario Drug Benefit Program, which provides
comprehensive drug benefits to all residents aged 65
or older in Ontario, Canada. We identified all patients
who had been taking lithium or valproic acid between
1993 and 2001 (prevalent users) and we further iden-
tified those patients who had not previously taken
lithium or valproic acid (new users). We restricted our
study to patients aged 66 or more to enable us to
examine their previous drug use for a minimum of
one year. Using unique encrypted health card
numbers, we linked data on this cohort to two other
large datasets—the Canadian Institute for Health
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